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Rheumatoid arthritis
STaTe of knowledge
nutrients and immune-inflammatory response  
in Ra
Rheumatoid arthritis (RA) is characterised by 
a systemic immune-inflammatory response, 
in genetically susceptible individuals exposed 
to environmental and endogenous triggers, 
including specific nutrients.1 The major path-
ways in RA are characterised by an intense 
inflammatory response, involving impaired 
immunoregulatory processes and the produc-
tion of different proinflammatory media-
tors.2 Research on possible risk factors has 
traditionally focused on triggers setting off 
disease, such as microbial/viral agents, ciga-
rette smoking and environmental pollution, 
hormonal imbalance and chronic stress, but 
with less focus in the past few decades on 
nutritional factors that can influence disease 
onset, progression and outcomes, possibly 
through epigenetic mechanisms.2 
More recently, simple and daily dietary 
factors have been implicated in the develop-
ment of RA, even directly through triggering 
inflammatory pathways: for example, the 
recent evidence that increased sodium chlo-
ride salt (figure 1), activates proinflammatory 
macrophages (M1), Th17 cells and decrease 
T-regulator cells, all crucial players in RA 
pathogenesis.3 In addition, sodium excretion 
was recently found higher in patients with 
early RA than in matched controls.4
Other interferences exerted by nutrients 
like cocoa, ginseng or capsaicin (pepper) on 
the RA pathways and mediators are reported in 
figure 1 and discussed in greater detail below.
Despite accumulating evidence over time, 
the important role that the diet plays on 
human health in general and more specif-
ically in chronic conditions such as RA, has 
been subject to much controversy. This has 
had direct impact on the most important 
stakeholders, the patients, who are the most 
frequent active seekers and ‘consumers’ of 
this crucial information.
evidence for the possible role of different ‘fatty 
diets’ in models and patients with Ra
An important reason for rheumatologists 
needing to pay attention to nutrition is 
in order to help control inflammation by 
encouraging the use of anti-inflammatory 
diets and decreasing the use of proinflamma-
tory ones. The notion of ‘inflammatory foods’ 
is becoming increasingly recognised across 
chronic diseases such as RA. The ‘modern 
diet’5 especially practised in Western cultures 
could be viewed as the greatest enemy of 
chronic inflammatory conditions like RA, 
whereby the increased consumption of 
refined carbohydrates, vegetable oils rich in 
omega-6 fatty acids and decreased consump-
tion of long-chain omega-3 fatty acids 
represent ‘the perfect nutritional storm’.6 
Supporting these observations, animal data 
have confirmed that a low ratio of n-6/n-3 
polyunsaturated fatty acids (PUFA) reduces 
adjuvant-induced arthritis in rats.7
Since the 1980s and early 1990s where 
health education initiatives advocated the 
consumption of antifat diets, in more recent 
times dietary fats have been increasingly 
recognised to have a positive impact on health 
and arthritis.8 Animal studies support that by 
inducing a collagen-induced arthritis (CIA), 
in a model of RA in mice consuming high-fat 
diet (HFD), a risk factor for RA, is related 
to inflammation but responds minimally 
to medication. HFD-CIA mice had a high 
level of α2-glycoprotein 1 (Azgp1), a soluble 
protein that stimulates lipolysis and fat los 
that causes increased IL-17; therefore, those 
mice showed more severe CIA. The same 
findings are observed in patients with RA.9 
Of particular interest, a recent study showed 
that obese mice fed with HFD had an earlier 
onset of CIA compared with mice on regular 
diet, with even a more sustained joint inflam-
mation in obese mice.10 As a matter of fact, 
despite established RA disease being unaf-
fected by obesity, the early and the resolution 
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phases of RA are impacted by obesity through different 
mechanisms. For example, conditioned media from RA 
adipose tissue can transform RA and wild-type naïve 
myeloid cells into M1 proinflammatory macrophages.10
On the other hand, the benefits of omega-3 fatty 
acids (figure 1) and of monounsaturated fatty acids 
(MUFA) (key components of the Mediterranean diet) in 
controlling disease activity in RA have been published11 
and also shown in human clinical trials.12 13 In addition, 
obesity, a global health problem, represents an important 
and rising comorbidity even on first presentation of RA14 
and appears to be a key determinant of insulin resis-
tance, even more so than circulating proinflammatory 
cytokines.15
what has been specifically shown for patients with Ra and 
what has not
Further important nutritional aspects have been specif-
ically shown for patients with RA. Taking a focus on 
the nutritional effects of RA pharmacotherapy, one 
cannot ignore the established side effects related to the 
disease-modifying treatments (DMARDs) including the 
anchor drug in RA, that is methotrexate,16 causing some 
kind of ‘iatrogenic malnutrition’, whether this is due to 
nausea, stomatitis, upset stomach, diarrhoea and other.
For some of the DMARDs, the gastrointestinal side 
effects can be particularly prominent with consequences 
on nutritional status and thus, indirectly, RA disease 
outcomes. Furthermore, the widespread and non-opti-
mised use of glucocorticoids (GCs) (high dosages, at the 
wrong time and of prolonged duration) can be ‘blamed’ 
at least for the well assessed increased weight gain/
body mass index and diabetes. The further interaction 
between some of these conditions adds to the disease 
burden in RA and requires specific dietary/pharmaco-
logical management.17 Therefore, as rheumatologists we 
should at the very least encourage reduction or elimina-
tion of carbohydrates and high sugar content foods and 
beverages in our patients with concomitant GC use.
Another important aspect in RA relates to the effects 
of pregnancy, where there exists strong evidence on the 
epigenetic/‘therapeutic’ effects of pregnancy states, due 
to the intense steroid hormonal changes; adherence to 
the Mediterranean diet during fetal development are 
key factors in the protection from metabolic syndrome 
(MS9.18 On the other hand, it is supportable, but not 
specifically shown, that omega-3 PUFA (n-3 PUFA) supple-
mentation of the maternal diet in pregnancy may provide 
a non-invasive intervention with significant potential to 
prevent the development of allergic and possibly other 
immune-mediated diseases, including RA.19
Furthermore, revolutionary treatments for RA, such 
as the TNF inhibitors, are becoming standard practice 
Figure 1 Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis 
are described. Selected nutritional effects on components of the ‘cascade also indicated. ACPA, anticitrullinated 
peptides autoantibodies; DCs, dendritic cells; RFs, rheumatoid factors.
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for most of the 21st century and despite their impressive 
potential to reduce or even halt overexpression of proin-
flammatory cytokines, they are not effective by them-
selves, for example, in increasing muscle mass. In fact, 
they increase fat mass and related metabolic/nutritional 
consequences.20 21
Microbiome, diet and Ra
The emerging role of the gut microbiome in RA must 
also be considered as evidence supports its impact on 
nutrition and disease progression.22 The human body 
contains millions of commensal bacteria (the micro-
biome), with the bowel being the most prevalent site of 
colonisation. The process of colonisation begins at birth, 
and despite interfering factors such as diet and drug use 
affecting the microbiome composition, by adulthood the 
gut bacteria are relatively consistent across local popula-
tions. Manipulation of the microbiome in inflammatory 
arthritis, both in animal and human models, offers a 
potential therapeutic target.22
For example, probiotics have been shown to lower the 
proinflammatory cytokine IL-6 in RA, although how this 
translates to clinically apparent effects remains unclear, 
emphasising the need for high-quality trials to investigate 
these links and prove or disprove the effects on clini-
cally apparent disease.23 Probiotics contain living healthy 
bacteria such as Bifidobacteria, Bacteroides-Porphyro-
monas-Prevotella, Bacteroides fragilis and the Eubac-
terium rectale-Clostridium coccoides species, that are 
significantly reduced in the gut microbiome of patients 
with RA. In contrast, bacteria such as Prevotella copri are 
found in 75% of people with new, untreated RA and are 
considered a possible risk factor for triggering disease.
A more a healthy diet (fibres) may lead to a more 
healthy gut microbiota, less active immune system and 
inflammatory reactions in the gut and finally leading to 
less inflammation systemically.24–27
As matter of fact, a healthy gut microbiota also releases 
food metabolites that are anti-inflammatory for the gut 
immune system and epithelium such as short-chain fatty 
acids (SCFA). The SCFA are regarded as one of the major 
microbial metabolites formed by microbial fermentation 
of dietary fibres, which can improve intestinal mucosal 
immunity,28
Therefore, recent randomised controlled clinical trials 
(RCTs) seem to provide evidence that specific probi-
otic supplementation exhibits anti-inflammatory effects, 
helps to increase daily activities and alleviates symptoms 
in patients with RA.29
why RheuMaTologiSTS Should CaRe abouT dieT in Ra
direct and indirect therapeutic effects of specific nutrients in 
Ra
Referring to a recent example of potential therapeutic 
effects of nutrients in RA, red hot chili peppers (capsa-
icin) (figure 1) have been suggested to play anti-inflamma-
tory roles by increasing anti-inflammatory macrophages 
(M2), modulating the neuroimmune response and 
decreasing neurogenic pain (topic effect).30 Recent 
research has focused on the evaluation of the efficacy of 
dietary antioxidants such as the phytomolecules31 and 
Coenzyme Q10 (CoQ10), an endogenous antioxidant,32 
with positive effects. Cocoa (figure 1) represents another 
nutrient of increasing interest because of its antioxidant 
properties, which are mainly attributed to the content of 
flavonoids such as (-)-epicatechin, catechin and procy-
anidins.33 In addition, regulatory activity on the secre-
tion of inflammatory mediators from macrophages and 
other leucocytes in vitro has been proven to be exerted 
by cocoa.
Interestingly, nanopowdered red ginseng (NRG) 
(figure 1) used together with methotrexate in arthritic 
mice significantly reduced cytokines including TNF-a, 
IL-6 and IL-1b and IgM and IgG1 and suggested the 
effectiveness of NRG at least in preventing type II colla-
gen-induced RA in mice.34 Such observations about 
specific nutrients also trigger questions around the value 
of supplementation in chronic inflammatory diseases 
such as RA.
Keeping a focus on evidence-based medicine, one 
important nutritional aspect in chronic immune/inflam-
matory diseases such as RA is related to the role and 
level of vitamin D, or better-said, the D hormone, since 
it is a true steroid hormone synthesised in the skin from 
7-dh-cholesterol under the action of the ultraviolet (UV) 
sun radiations.35 Since only 20% of the daily need of 
vitamin D can be obtained by the diet (80% from UV), 
vitamin D supplementation is a more accepted practice 
with important control (as steroid hormone) of both 
innate and adaptive immune response, especially with 
increasing recognition that vitamin D insufficiency/defi-
ciency is a frequent observation in RA (figure 1).36
Patient-reported outcomes in RA appear to be of value 
in detecting/predicting by clinical symptoms, the effects 
of the epidemic deficiency of vitamin D/D hormone 
in Europe and especially during the winter.36 Further 
adding to the evidence base, data from a recent large 
study suggest that higher intake of dietary vitamin D as 
well as omega-3 fatty acids, during the year preceding 
DMARD initiation may be associated with better treat-
ment results in patients with early RA.37
Rheumatoid cachexia
Another important reason nutrition should not be 
neglected in RA is in order to prevent and/or treat ‘rheu-
matoid cachexia’. Evidence suggests that any ongoing, 
uncontrolled and chronic inflammatory process in RA, 
involves adverse effects on body composition, including 
in particular reduced muscle and increased fat mass.37 38 
Rheumatoid cachexia refers to these effects, which 
although rarely apparent, due to the loss of lean body 
mass being counter-balanced by the maintenance or gain 
in fat mass,38 is associated with poor prognosis.39
Evidence also suggests that nutrition should be 
part of routine care in patients with RA with muscle 
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wasting disorders.40 More specifically, up to 75% of 
patients with RA believe that food and nutrition play 
an important role in their symptom severity, with 50% 
of patients with RA reportedly trying some form of 
dietary manipulation in an attempt to attenuate symp-
tomology.39 40 A previous study investigated the effects 
of a daily mixture of β-hydroxy-β-methylbutyrate, gluta-
mine and arginine (HMB/GLN/ARG) protein 12-week 
supplementation in 40 patients  with RA with rheuma-
toid cachexia.41 The results showed that both HMB/
GLN/ARG and a control mixture of other non-essen-
tial amino acids (alanine, glutamic acid, glycine and 
serine) were both equally effective in increasing lean 
mass (~0.4 kg) and improving some measures of phys-
ical function and strength.42
In addition, common mental health comorbidities 
in RA such as depression and anxiety might influence 
the nutritional status by inducing anorexia-cachexia42 
Mental health comorbidities can affect life style and 
nutritional status43 with detrimental outcomes. In 
this respect, supplements containing amino acids are 
believed to be beneficial, since they are converted to 
neurotransmitters which in turn alleviate depression 
and other mental health problems.44 These obser-
vations further highlight the value of personalising 
dietary regimes for patients with RA and their respec-
tive comorbidities.
diet and cardiovascular risk in Ra
Several clinical, epidemiological and experimental 
evidence suggest that consumption of the Mediterranean 
Diet reduces the incidence of pathologies related to the 
immune system, oxidative stress and chronic inflamma-
tion including atherosclerosis and cardiovascular disease.
These reductions can be partially attributed to extra 
virgin olive oil (EVOO) consumption which has been 
described as a key bioactive food because of its high nutri-
tional quality and its particular composition of fatty acids, 
vitamins and polyphenols.45 Indeed, the beneficial effects 
of EVOO have been linked to its fatty acid composition, 
which is very rich in MUFA, and has moderate saturated 
and PUFA.
Several RCTs to assess potential changes in RA inflam-
mation and related cardiovascular (CV) risk after oral 
intake of ω-3 PUFA have come to light. A meta-anal-
ysis evaluating 20 RCTs, involving 717 patients with RA 
in the intervention group and 535 patients with RA in 
the control group was recently published. Despite the 
evidence of overall low quality trials, consumption of 
ω-3 fatty acids was found to significantly improve eight 
disease-activity-related markers. Regarding inflammation, 
only leukotriene B4 was reduced (five trials, P<0.001), 
whereas a significant amelioration was found for blood 
triacylglycerol levels (three trials, P=0.012). The benefi-
cial properties of ω-3 PUFA on RA disease activity confirm 
the results of previous meta-analyses. On the other hand, 
a large recent study demonstrated that statin therapy 
is associated with a lower event rate of new-onset acute 
coronary syndrome in patients with RA, with the benefi-
cial effect being dose-responsive.46
Prevention of metabolic effects of glucocorticoids in Ra
Patients who are taking exogenous GCs might also be 
more susceptible to poor food choices; however, the 
effect of increased fat consumption in combination 
with elevated exogenous GCs has only recently been 
investigated.47 These studies have shown that the meta-
bolic effects initiated through exogenous GC treat-
ment are significantly amplified when combined with 
a HFD. Animal data confirm that rodents on a HFD 
and elevated GCs demonstrate more glucose intoler-
ance, hyperinsulinaemia, visceral adiposity and skeletal 
muscle lipid deposition when compared with rodents 
subjected to either treatment on its own. Exercise has 
recently been shown to be a viable therapeutic option 
for GC-treated, high-fat fed rodents. Clinically, these 
mechanistic studies again underscore the importance 
of a low-fat diet and increased physical activity levels 
when patients, like in the case of patients with RA, are 
given a course of GC treatment. In fact, even at low 
doses, prednisolone exerts adverse effects on fat metab-
olism, which could exacerbate insulin resistance and 
increase CV risk.48
ConCluSion
All these observations lead us to further stress and 
conclude that nutrition matters and importantly in RA, 
it plays a role in disease progression and outcomes. 
Although origins of our understanding of diet and 
disease stem back to paleontological times,49 the 
subject seems to be receiving some ‘revival’ in modern 
times. Despite this, nutrition and the impact on chronic 
musculoskeletal disease including RA remain a poorly 
taught subject, both in medical schools and in post-
graduate rheumatology training. One would argue that 
addressing nutrition in our patients is not the ‘job’ of 
a rheumatologist, but instead of a dietician. Whereas 
this may be partly true, rheumatologists are the ones 
who come face to face with patients and their families 
and access to a dietician may not always be easily and 
readily available or at all possible. Similarly, working 
closely in a multidisciplinary team setting with dieti-
cians is certainly optimal, but not always possible. We 
therefore advocate that at least some basic knowledge 
on the subject is warranted by rheumatologists in order 
to appropriately guide on the best ‘recipe’ for their 
patients with RA.
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